Skip to main content
. 2018 Jul 4;12:452. doi: 10.3389/fnins.2018.00452

FIGURE 1.

FIGURE 1

(A) Availability of antibodies in CNS regions after immunotherapy of PLP-α-synuclein mice (n = 7 for all groups). (B) Level of soluble and (C) insoluble total α-synuclein species in the CNS of PLP-α-synuclein mice (nvehicle = 8, nrec47 = 9) tested by ELISA (p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001).

HHS Vulnerability Disclosure